Non-invasive assessment of liver fibrosis and prognosis

an update on serum and elastography markers

Uchenna Agbim, Sumeet K. Asrani

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: Non-invasive assessment of fibrosis is increasingly utilized in clinical practice to diagnose hepatic fibrosis. Non-invasive assessment of liver fibrosis relies on biologic and/or physical properties to assess tissue fibrosis. Serum markers estimate fibrosis by incorporating markers reflecting hepatic function (indirect markers) and/or markers measuring extracellular matrix degradation/fibrogenesis (direct markers). Radiology based techniques relay the mechanical properties and stiffness of a tissue, with increased stiffness associated with more advanced fibrosis. Areas covered: In this comprehensive review, the recent literature discussing serum markers and elastography-based techniques will be covered. These modalities are also explored in the setting of various liver diseases. Expert opinion: The etiology of liver disease and clinical context should be taken into consideration when non-invasive markers are incorporated in clinical practice. Non-invasive assessment of fibrosis has been most extensively utilized in hepatitis C, followed by hepatitis B and nonalcoholic fatty liver disease, but its role remains less developed in other etiologies of liver disease such as alcohol-associated liver disease and autoimmune liver disease. The role of non-invasive markers in predicting progression or regression of fibrosis, development of liver-related events and survival needs to be further explored.

Original languageEnglish (US)
Pages (from-to)361-374
Number of pages14
JournalExpert Review of Gastroenterology and Hepatology
Volume13
Issue number4
DOIs
StatePublished - Apr 3 2019

Fingerprint

Elasticity Imaging Techniques
Liver Cirrhosis
Fibrosis
Biomarkers
Liver Diseases
Liver
Expert Testimony
Hepatitis C
Hepatitis B
Radiology
Autoimmune Diseases
Extracellular Matrix
Alcohols

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Non-invasive assessment of liver fibrosis and prognosis : an update on serum and elastography markers. / Agbim, Uchenna; Asrani, Sumeet K.

In: Expert Review of Gastroenterology and Hepatology, Vol. 13, No. 4, 03.04.2019, p. 361-374.

Research output: Contribution to journalArticle

@article{95d3e6e374aa463f82c514241460136e,
title = "Non-invasive assessment of liver fibrosis and prognosis: an update on serum and elastography markers",
abstract = "Introduction: Non-invasive assessment of fibrosis is increasingly utilized in clinical practice to diagnose hepatic fibrosis. Non-invasive assessment of liver fibrosis relies on biologic and/or physical properties to assess tissue fibrosis. Serum markers estimate fibrosis by incorporating markers reflecting hepatic function (indirect markers) and/or markers measuring extracellular matrix degradation/fibrogenesis (direct markers). Radiology based techniques relay the mechanical properties and stiffness of a tissue, with increased stiffness associated with more advanced fibrosis. Areas covered: In this comprehensive review, the recent literature discussing serum markers and elastography-based techniques will be covered. These modalities are also explored in the setting of various liver diseases. Expert opinion: The etiology of liver disease and clinical context should be taken into consideration when non-invasive markers are incorporated in clinical practice. Non-invasive assessment of fibrosis has been most extensively utilized in hepatitis C, followed by hepatitis B and nonalcoholic fatty liver disease, but its role remains less developed in other etiologies of liver disease such as alcohol-associated liver disease and autoimmune liver disease. The role of non-invasive markers in predicting progression or regression of fibrosis, development of liver-related events and survival needs to be further explored.",
author = "Uchenna Agbim and Asrani, {Sumeet K.}",
year = "2019",
month = "4",
day = "3",
doi = "10.1080/17474124.2019.1579641",
language = "English (US)",
volume = "13",
pages = "361--374",
journal = "Expert Review of Gastroenterology and Hepatology",
issn = "1747-4124",
publisher = "Expert Reviews Ltd.",
number = "4",

}

TY - JOUR

T1 - Non-invasive assessment of liver fibrosis and prognosis

T2 - an update on serum and elastography markers

AU - Agbim, Uchenna

AU - Asrani, Sumeet K.

PY - 2019/4/3

Y1 - 2019/4/3

N2 - Introduction: Non-invasive assessment of fibrosis is increasingly utilized in clinical practice to diagnose hepatic fibrosis. Non-invasive assessment of liver fibrosis relies on biologic and/or physical properties to assess tissue fibrosis. Serum markers estimate fibrosis by incorporating markers reflecting hepatic function (indirect markers) and/or markers measuring extracellular matrix degradation/fibrogenesis (direct markers). Radiology based techniques relay the mechanical properties and stiffness of a tissue, with increased stiffness associated with more advanced fibrosis. Areas covered: In this comprehensive review, the recent literature discussing serum markers and elastography-based techniques will be covered. These modalities are also explored in the setting of various liver diseases. Expert opinion: The etiology of liver disease and clinical context should be taken into consideration when non-invasive markers are incorporated in clinical practice. Non-invasive assessment of fibrosis has been most extensively utilized in hepatitis C, followed by hepatitis B and nonalcoholic fatty liver disease, but its role remains less developed in other etiologies of liver disease such as alcohol-associated liver disease and autoimmune liver disease. The role of non-invasive markers in predicting progression or regression of fibrosis, development of liver-related events and survival needs to be further explored.

AB - Introduction: Non-invasive assessment of fibrosis is increasingly utilized in clinical practice to diagnose hepatic fibrosis. Non-invasive assessment of liver fibrosis relies on biologic and/or physical properties to assess tissue fibrosis. Serum markers estimate fibrosis by incorporating markers reflecting hepatic function (indirect markers) and/or markers measuring extracellular matrix degradation/fibrogenesis (direct markers). Radiology based techniques relay the mechanical properties and stiffness of a tissue, with increased stiffness associated with more advanced fibrosis. Areas covered: In this comprehensive review, the recent literature discussing serum markers and elastography-based techniques will be covered. These modalities are also explored in the setting of various liver diseases. Expert opinion: The etiology of liver disease and clinical context should be taken into consideration when non-invasive markers are incorporated in clinical practice. Non-invasive assessment of fibrosis has been most extensively utilized in hepatitis C, followed by hepatitis B and nonalcoholic fatty liver disease, but its role remains less developed in other etiologies of liver disease such as alcohol-associated liver disease and autoimmune liver disease. The role of non-invasive markers in predicting progression or regression of fibrosis, development of liver-related events and survival needs to be further explored.

UR - http://www.scopus.com/inward/record.url?scp=85062614612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062614612&partnerID=8YFLogxK

U2 - 10.1080/17474124.2019.1579641

DO - 10.1080/17474124.2019.1579641

M3 - Article

VL - 13

SP - 361

EP - 374

JO - Expert Review of Gastroenterology and Hepatology

JF - Expert Review of Gastroenterology and Hepatology

SN - 1747-4124

IS - 4

ER -